ATE151642T1 - Behandlung für entzündungserkrankung des darmes - Google Patents

Behandlung für entzündungserkrankung des darmes

Info

Publication number
ATE151642T1
ATE151642T1 AT93904830T AT93904830T ATE151642T1 AT E151642 T1 ATE151642 T1 AT E151642T1 AT 93904830 T AT93904830 T AT 93904830T AT 93904830 T AT93904830 T AT 93904830T AT E151642 T1 ATE151642 T1 AT E151642T1
Authority
AT
Austria
Prior art keywords
treatment
intestinal
inflammatory disease
tissus
ibd
Prior art date
Application number
AT93904830T
Other languages
English (en)
Inventor
Roy R Lobb
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25268692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE151642(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE151642T1 publication Critical patent/ATE151642T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93904830T 1992-02-12 1993-02-02 Behandlung für entzündungserkrankung des darmes ATE151642T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83513992A 1992-02-12 1992-02-12

Publications (1)

Publication Number Publication Date
ATE151642T1 true ATE151642T1 (de) 1997-05-15

Family

ID=25268692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93904830T ATE151642T1 (de) 1992-02-12 1993-02-02 Behandlung für entzündungserkrankung des darmes

Country Status (11)

Country Link
EP (1) EP0625912B1 (de)
JP (3) JPH07506566A (de)
AT (1) ATE151642T1 (de)
AU (1) AU674302B2 (de)
CA (1) CA2129637C (de)
DE (1) DE69309906T2 (de)
DK (1) DK0625912T3 (de)
ES (1) ES2103468T3 (de)
GR (1) GR3024041T3 (de)
HK (1) HK1007683A1 (de)
WO (1) WO1993015764A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1994011027A1 (en) 1992-11-13 1994-05-26 Board Of Regents Of University Of Washington Peripheralization of hematopoietic stem cells
EP0682529B2 (de) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antikörper zur behandlung von insulinabhängigem diabetes
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DE69535133T2 (de) * 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU757873B2 (en) 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
EP2289941A3 (de) 2002-02-25 2012-01-18 Elan Pharmaceuticals Inc. Verabreichung von Wirkstoffen zur Behandlung von Entzündungen
EP1700850B1 (de) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalaninderivat
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP4652356B2 (ja) 2007-02-26 2011-03-16 アルプス電気株式会社 ターンシグナルスイッチ装置
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
EP3466977B1 (de) 2010-04-16 2022-01-05 Biogen MA Inc. Anti-vla-4-antikörper
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
CN109884295B (zh) * 2017-12-25 2022-03-08 苏州和锐生物科技有限公司 假单胞菌多肽、抗体捕获器件及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (de) * 1987-11-02 1994-12-07 Baylor College Of Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
CA2120500A1 (en) * 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules

Also Published As

Publication number Publication date
JPH07506566A (ja) 1995-07-20
DE69309906D1 (de) 1997-05-22
CA2129637A1 (en) 1993-08-19
JP4108572B2 (ja) 2008-06-25
WO1993015764A1 (en) 1993-08-19
EP0625912A1 (de) 1994-11-30
GR3024041T3 (en) 1997-10-31
CA2129637C (en) 1999-05-04
JP2007045843A (ja) 2007-02-22
HK1007683A1 (en) 1999-04-23
ES2103468T3 (es) 1997-09-16
AU3605993A (en) 1993-09-03
AU674302B2 (en) 1996-12-19
EP0625912B1 (de) 1997-04-16
JP2004002472A (ja) 2004-01-08
DK0625912T3 (da) 1997-10-27
DE69309906T2 (de) 1997-11-06

Similar Documents

Publication Publication Date Title
ATE151642T1 (de) Behandlung für entzündungserkrankung des darmes
ATE332159T1 (de) System zum sammeln von blut ohne es zu beschädigen
DE69309044T2 (de) Behandlung von asthma
BR9712488A (pt) Anticorpo anti-hm 1.24 humano remodelado
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
ES2094733T3 (es) Deteccion de enfermedades o disfunciones neurologicas.
DE3855525T2 (de) Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS.
ATE194497T1 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
CA2034881A1 (en) Factor x-laci hybrid protein
EP0937982A3 (de) Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis
FR2658197B1 (fr) Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
SE8904007D0 (sv) Monoklona antikroppar och diagnostiseringsmetod
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
FR2618439B1 (fr) Sequences d'amino-acides reproduisant au moins en partie la sequence des lectines animales et humaines, leurs procedes d'obtention, leurs applications diagnostiques et therapeutiques
DE69529405T2 (de) Pd-ecgf / thymidin phosphorylase spezifischer monoklonaler antikörper
RU96109171A (ru) Способ идентификации тела погибшего
DE69023500D1 (de) Verfahren zum nachweis von antikörpern gegen streptokinase.
RU93004826A (ru) Способ мездрения кож и шкур
MX9700413A (es) Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso.
RU93000004A (ru) Вещество для лечения подкожной фибрасаркомы и способ его получения
RU95105698A (ru) Способ получения сыворотки против pasteurella multocida
KR970006494A (ko) 고정화 아미노펩티다제 엠을 이용한 천연형 인간성장호르몬의 제조 방법
UA15941A (uk) Спосіб діагhостики початкових стадій гіпертоhічhої хвороби
RU94005147A (ru) Способ прогнозирования расширения язвенного дефекта при язвенной болезни желудка и двенадцатиперстной кишки в стадии обострения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked